Login to Your Account



Clinic Roundup


Thursday, August 16, 2012
• Senesco Technologies Inc., of Bridgewater, N.J., said it completed the first cohort of patients in its Phase Ib/IIa trial in multiple myeloma, showing that SNS01-T was safe and well tolerated and met the criteria for stable disease in two of the three evaluable patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription